Breaking News Instant updates and real-time market news.

EVR

Evercore Partners

$93.55

0.4 (0.43%)

, LNCE

Snyder's-Lance

$49.96

(0.00%)

18:06
03/21/18
03/21
18:06
03/21/18
18:06

S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices

S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: S&P SmallCap 600 constituent Evercore (EVR) will replace Snyder's-Lance (LNCE) in the S&P MidCap 400, and MGP Ingredients (MGPI) will replace Evercore the S&P SmallCap 600 effective prior to the open of trading on Monday, March 26. S&P 500 constituent Campbell Soup (CPB) is acquiring Snyder's-Lance in a deal expected to close on or about that date pending final conditions. Tabula Rasa HealthCare (TRHC) will replace Almost Family (AFAM) in the S&P SmallCap 600 effective prior to the open of trading on Monday, April 2. S&P SmallCap 600 constituent LHC Group (LHCG) is acquiring Almost Family in a deal expected to be completed on or about that date pending final conditions.

EVR

Evercore Partners

$93.55

0.4 (0.43%)

LNCE

Snyder's-Lance

$49.96

(0.00%)

MGPI

MGP Ingredients

$80.36

-3.07 (-3.68%)

CPB

Campbell Soup

$42.17

-0.95 (-2.20%)

TRHC

Tabula Rasa HealthCare

$38.43

0.23 (0.60%)

AFAM

Merged with LHCG

$56.55

0.3 (0.53%)

LHCG

LHC Group

$61.88

0.37 (0.60%)

  • 21

    Mar

  • 24

    Apr

  • 29

    May

  • 30

    May

EVR Evercore Partners
$93.55

0.4 (0.43%)

01/09/18
UBSW
01/09/18
UPGRADE
Target $105
UBSW
Buy
Evercore Partners upgraded to Buy from Neutral at UBS
UBS analyst Brennan Hawken upgraded Evercore Partners to Buy and raised his price target for the shares to $105 from $82. The analyst estimates Evercore's pipeline has more than doubled since October and he expects it to continue growing given the positive momentum. He believes Evercore has "meaningful leverage to large deals" and finds the current valuation multiple as reasonable.
05/23/17
GSCO
05/23/17
DOWNGRADE
Target $79
GSCO
Neutral
Evercore Partners downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Conor Fitzgerald downgraded Evercore Partners to Neutral citing more balanced risk/reward and said growth prospects are better understood by the market. Further, the analyst believes revenue growth may have slowed and political uncertainty could impact 2H revenue. Fitzgerald lowered his price target on Evercore to $79 from $87.
03/27/17
KBWI
03/27/17
INITIATION
Target $82
KBWI
Market Perform
Evercore Partners assumed with a Market Perform at Keefe Bruyette
Price target $82.
LNCE Snyder's-Lance
$49.96

(0.00%)

12/18/17
BMOC
12/18/17
DOWNGRADE
Target $49
BMOC
Market Perform
Snyder's-Lance cut to Market Perform at BMO Capital after buyout rumor rally
As reported earlier, BMO Capital analyst Amit Sharma downgraded Snyder's-Lance (LNCE) to Market Perform from Outperform in the wake of a 20% spike in the company stock that followed speculation of an acquisition by Cambell Soup (CPB). Sharma says the potential of a downside in the stock price at this level on "no deal" is greater than the upside, though stock could still rally up to 14% if a takeout does pan out. The analyst raises his price target to $49 from $43 despite the downgrade, noting that the company is an attractive target thanks to its portfolio of strong snacking brands, margin expansion potential, and the presence of multiple likely suitors.
12/19/17
RHCO
12/19/17
NO CHANGE
Target $50
RHCO
Hold
Snyder's-Lance price target raised to $50 from $35 at SunTrust
SunTrust analyst William Chappell raised his price target on Snyder's-Lance (LNCE) to $50 after the announcement that the company was being acquired by Campbell Soup (CPB). The target price is equal to the deal price, reflecting the analyst's view that no other bidders will emerge. Chappell keeps his Hold rating on Snyder's-Lance.
12/22/17
LOOP
12/22/17
NO CHANGE
Target $38
LOOP
Hold
Hain unlikely to receive premium in a takeover, says Loop Capital
Following the acquisitions of Amplify Snack Brands (BETR) and Snyder's-Lance (LNCE), Loop Capital analyst Andrew Wolf revisited his outlook for Hain Celestial Group (HAIN) as an acquisition candidate. The analyst's sum-of-the-parts valuation range for the company remains at $42 to $56 per share, representing a premium range of 1% to 35% to the current share price. Hain, however, is not likely to receive much of a premium valuation in a takeout because its core domestic business is barely growing, in contrast to the companies that have been acquired, Wolf tells investors in a research note. He keeps a Hold rating on the stock with a $38 price target.
02/06/18
JEFF
02/06/18
DOWNGRADE
Target $50
JEFF
Hold
Snyder's-Lance downgraded to Hold from Buy at Jefferies
Jefferies analyst Akshay Jagdale downgraded Snyder's-Lance (LNCE) to Hold citing the acquisition by Campbell Soup (CPB). The chance of a higher, alternative bid emerging is "fairly remote" given the transaction's rich valuation, Jagdale tells investors in a research note. The analyst raised his price target for the shares to $50 from $44 and expects the deal to close in Q2.
MGPI MGP Ingredients
$80.36

-3.07 (-3.68%)

05/05/17
SIDC
05/05/17
DOWNGRADE
SIDC
Neutral
MGP Ingredients downgraded to Neutral from Buy at Sidoti
Sidoti downgraded MGP Ingredients to Neutral citing valuation and mainly the "massive" buildup across the industry in aging whiskey inventory.
12/05/17
STFL
12/05/17
INITIATION
STFL
Hold
MGP Ingredients initiated with a Hold at Stifel
01/29/18
CHLM
01/29/18
NO CHANGE
Target $105
CHLM
Buy
MGP Ingredients price target raised to $105 from $90 at Craig-Hallum
Craig-Hallum analyst Alex Fuhrman raised his price target for MGP Ingredients to $105 from $90 as he believes multi-year strategy to squirrel away aging distillate has the company positioned for earnings power exceeding $3/$90M in EPS/EBITDA. The analyst reiterates a Buy rating on the shares.
01/31/18
SIDC
01/31/18
UPGRADE
SIDC
Buy
MGP Ingredients upgraded to Buy from Neutral at Sidoti
Sidoti analyst Francesco Pellegrino upgraded MGP Ingredients to Buy and raised its price target to $111 from $58 on a higher quality inventory outlook that supports $5 in earnings power by 2021-2022.
CPB Campbell Soup
$42.17

-0.95 (-2.20%)

02/28/18
PIPR
02/28/18
DOWNGRADE
PIPR
Underweight
Campbell Soup downgraded to Underweight from Neutral at Piper Jaffray
03/01/18
PIPR
03/01/18
DOWNGRADE
Target $45
PIPR
Underweight
Campbell Soup downgraded to Underweight from Neutral at Piper Jaffray
Piper Jaffray analyst Michael Lavery downgraded Campbell Soup to Underweight and lowered his price target for the shares to $45 from $53. The analyst sees multiple expansion as unlikely given his expectations for 1.0%-1.5% earnings growth in fiscal 2019. Higher interest rates and lower than expected Snyder-Lance operating contribution weigh on the analyst's earnings expectations.
03/01/18
03/01/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Campbell Soup (CPB) downgraded to Underweight from Neutral at Piper Jaffray by analyst Michael Lavery, who sees multiple expansion as unlikely given his expectations for 1%-1.5% earnings growth in fiscal 2019. Higher interest rates and lower than expected Snyder-Lance operating contribution weigh on the analyst's earnings expectations. 2. MannKind (MNKD) downgraded to Sell from Hold at Maxim by analyst Jason Kolbert, who said the company's Afrezza revenues of $4.5M were at the lower end of recently-lowered guidance and were " clearly disappointing given management's robust marketing plans". Kolbert added that the company has just $44M of cash remaining, having burned through about $120M last year. 3. Darling Ingredients (DAR) downgraded to Neutral from Buy at Goldman Sachs by analyst Adam Samuelson. While the company's Q4 results came in modestly above expectations, the analyst finds the outlook for roughly flat EBITDA in the base business despite recent growth investments disappointing. Samuelson sees a less attractive risk/reward for Darling post the Q4 results. Shares were also downgraded to Market Perform from Outperform at BMO Capital by analyst Kenneth Zaslow, who said his undamental view on the company has not changed, pointing to less compelling risk-reward based on limited upside in the stock price and some near-term headwinds. 4. Gibraltar Industries (ROCK) downgraded to Sector Weight from Overweight at KeyBanc by analyst Kenneth Zener, who said the risk to return is currently balanced. The analyst awais clarity on the company's next portfolio addition and wants to sees a "steady cadence of Solar EBIT margins." He believes, however, the Gibraltar is executing well post its Q4 results. 5. Mohawk (MHK) downgraded to Buy from Conviction Buy at Goldman Sachs. Analyst Samuel Eisner removed Mohawk from the Conviction Buy List citing near-term risks from rising rates and 1H18 risks from increasing costs and ramping capacity that could put a lid on shares near-term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TRHC Tabula Rasa HealthCare
$38.43

0.23 (0.60%)

03/13/18
PIPR
03/13/18
NO CHANGE
Target $43
PIPR
Overweight
Tabula Rasa price target raised to $43 from $36 at Piper Jaffray
Piper Jaffray analyst Sean Wieland raised his price target for Tabula Rasa HealthCare to $43 saying the company beat Q4 estimates and guided higher on revenue and profitability both organically and inorganically. He believes the company's momentum continues into 2018 and keeps an Overweight rating on the shares. New catalysts could drive further upside to numbers this year, the analyst contends.
01/04/18
SBSH
01/04/18
INITIATION
Target $37
SBSH
Buy
Tabula Rasa HealthCare initiated with a Buy at Citi
Citi analyst Stephanie Davis started Tabula Rasa HealthCare with a Buy rating and $37 price target. The analyst believes the company's "peer leading" solutions, dominance of the underpenetrated PACE market and an increasing focus on unnecessary hospitalizations should drive outsized growth in the coming years.
12/11/17
WBLR
12/11/17
INITIATION
WBLR
Outperform
Tabula Rasa HealthCare initiated with an Outperform at William Blair
William Blair starts Tabula Rasa HealthCare with an Outperform rating.
12/19/17
OPCO
12/19/17
INITIATION
Target $35
OPCO
Outperform
Tabula Rasa HealthCare initiated with an Outperform at Oppenheimer
Oppenheimer analyst Mohan Naidu started Tabula Rasa HealthCare with an Outperform rating and $35 price target, noting that its proprietary medication risk and therapy solutions are enabling a significant shift in care for the elderly through PACE by focusing on eliminating adverse drug events and dealing with complex, multiple-medication regimens at home.
AFAM Merged with LHCG
$56.55

0.3 (0.53%)

11/20/17
RBCM
11/20/17
DOWNGRADE
Target $62
RBCM
Sector Perform
Almost Family downgraded to Sector Perform at RBC Capital after LHC mergerLHC Group
As noted earlier, RBC Capital analyst Frank Morgan downgraded Almost Family (AFAM) to Sector Perform from Outperform but raised his price target to $62 from $54 to reflect the implied pricing of the merger announced last week. Morgan says the stock-for-stock transaction with LHC Group (LHCG) is positive, creating the largest in-home service provider in the industry. The analyst also notes that given the low overlap in the two companies' operations, he does not anticipate any antitrust issues related to the merger.
11/17/17
OPCO
11/17/17
NO CHANGE
Target $85
OPCO
Outperform
LHC Group price target raised to $85 from $80 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn raised his price target for LHC Group (LHCG) to $85 saying the merger with Almost Family (AFAM) is "highly favorable" given its strategic and financial benefits. The analyst continues to be a buyer of the shares at current levels. He notes that the all-stock nature of the transaction preserves LHC's balance sheet for additional acquisition opportunities going forward. Wiederhorn keeps an Outperform rating on the shares.
11/16/17
JPMS
11/16/17
NO CHANGE
JPMS
Neutral
Almost Family acquired for 16% premium, says JPMorgan
JPMorgan analyst Gary Taylor says Almost Family's (AFAM) merger of equals with LHC Group (LHCG) amounts to a takeover at a 16% premium, based on LHC's closing price yesterday. Regarding antitrust, the analyst notes that while the deal would propel the third and fourth largest players in the home-health industry to a number two position behind Kindred Healthcare (KND), the industry is "tremendously fragmented." Further, Taylor believes the merger agreement contains "onerous divestiture language." The analyst has a Neutral rating on Almost Family with a $59 price target.
11/20/17
RBCM
11/20/17
DOWNGRADE
RBCM
Sector Perform
Almost Family downgraded to Sector Perform from Outperform at RBC Capital
LHCG LHC Group
$61.88

0.37 (0.60%)

11/22/17
11/22/17
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Nutanix (NTNX) initiated with a Buy at Needham. 2. Regenxbio (RGNX) and Sangamo (SGMO) were initiated with an Overweight at Barclays. 3. Amedisys (AMED), HealthSouth (HLS), LHC Group (LHCG), and LifePoint (LPNT) were initiated with an Outperform at William Blair. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/21/17
WBLR
11/21/17
INITIATION
WBLR
Outperform
LHC Group initiated with an Outperform at William Blair
William Blair started LHC Group with an Outperform rating.

TODAY'S FREE FLY STORIES

IYR

DJ US Real Estate Index Fund

$80.72

-0.04 (-0.05%)

06:44
08/14/18
08/14
06:44
08/14/18
06:44
Technical Analysis
DJ US Real Estate Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MXIM

Maxim Integrated

$61.41

0.02 (0.03%)

06:44
08/14/18
08/14
06:44
08/14/18
06:44
Recommendations
Maxim Integrated analyst commentary  »

Maxim Integrated position…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

IBB

iShares Nasdaq Biotechnology Index

$116.54

-0.14 (-0.12%)

06:43
08/14/18
08/14
06:43
08/14/18
06:43
Technical Analysis
iShares Nasdaq Biotechnology Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LABD

Daily S&P Biotech Bear 3x Shares

$26.10

0.41 (1.60%)

06:42
08/14/18
08/14
06:42
08/14/18
06:42
Technical Analysis
Daily S&P Biotech Bear 3x Shares: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWH

MSCI Hong Kong Index

$24.13

-0.165 (-0.68%)

06:42
08/14/18
08/14
06:42
08/14/18
06:42
Technical Analysis
MSCI Hong Kong Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWG

iShares MSCI Germany

$29.59

-0.13 (-0.44%)

06:41
08/14/18
08/14
06:41
08/14/18
06:41
Technical Analysis
iShares MSCI Germany: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IJR

iShares Core S&P Small Cap ETF

$86.82

-0.4 (-0.46%)

06:41
08/14/18
08/14
06:41
08/14/18
06:41
Technical Analysis
iShares Core S&P Small Cap ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VERU

Veru Inc.

$2.06

-0.1 (-4.63%)

06:40
08/14/18
08/14
06:40
08/14/18
06:40
Earnings
Veru reports Q3 EPS (15c), consensus (8c) »

Reports Q3 revenue $5.5M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

EEM

MSCI Emerging Markets Index

$42.50

-0.695 (-1.61%)

06:39
08/14/18
08/14
06:39
08/14/18
06:39
Technical Analysis
MSCI Emerging Markets Index: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EYEN

Eyenovia

$5.55

-0.1 (-1.77%)

06:39
08/14/18
08/14
06:39
08/14/18
06:39
Earnings
Eyenovia reports Q2 EPS (33c), consensus (42c) »

Reports Q2 revenue $0,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

MSFT

Microsoft

$108.24

-0.81 (-0.74%)

, AMZN

Amazon.com

$1,895.51

9.52 (0.50%)

06:39
08/14/18
08/14
06:39
08/14/18
06:39
Periodicals
Microsoft still trying to find Cortana's voice, WSJ reports »

Microsoft (MSFT) is…

MSFT

Microsoft

$108.24

-0.81 (-0.74%)

AMZN

Amazon.com

$1,895.51

9.52 (0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 04

    Sep

  • 12

    Sep

  • 13

    Sep

EWW

iShares MSCI Mexico

$49.56

-0.065 (-0.13%)

06:39
08/14/18
08/14
06:39
08/14/18
06:39
Technical Analysis
iShares MSCI Mexico: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UUP

PowerShares DB US Dollar Index Up

$25.50

0.01 (0.04%)

06:38
08/14/18
08/14
06:38
08/14/18
06:38
Technical Analysis
PowerShares DB US Dollar Index Up: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UDN

PowerShares DB US Dollar Index Down

$21.24

-0.01 (-0.05%)

06:38
08/14/18
08/14
06:38
08/14/18
06:38
Technical Analysis
PowerShares DB US Dollar Index Down: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SESN

Sesen Bio

$1.89

0.09 (5.00%)

06:37
08/14/18
08/14
06:37
08/14/18
06:37
Earnings
Sesen Bio reports Q2 EPS (16c), consensus (14c) »

Reports Q2 revenue $0,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHAP

Chaparral Energy

$17.77

(0.00%)

06:36
08/14/18
08/14
06:36
08/14/18
06:36
Hot Stocks
Chaparral raises FY18 average daily production view to 19.0MBoe/d-20.0MBoe/d »

Previous FY18 average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

UHS

Universal Health

$124.44

-0.01 (-0.01%)

06:36
08/14/18
08/14
06:36
08/14/18
06:36
Initiation
Universal Health initiated  »

Universal Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THC

Tenet

$32.54

0.28 (0.87%)

06:35
08/14/18
08/14
06:35
08/14/18
06:35
Initiation
Tenet initiated  »

Tenet initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HD

Home Depot

$194.11

-2.19 (-1.12%)

06:35
08/14/18
08/14
06:35
08/14/18
06:35
Technical Analysis
Technical Take: Home Depot moves higher after results »

The shares were last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

AAP

Advance Auto Parts

$144.79

-1.52 (-1.04%)

06:35
08/14/18
08/14
06:35
08/14/18
06:35
Hot Stocks
Advance Auto Parts announces new $600M share repurchase program »

On August 8, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

HCA

HCA Healthcare

$128.74

0.57 (0.44%)

06:35
08/14/18
08/14
06:35
08/14/18
06:35
Initiation
HCA Healthcare initiated  »

HCA Healthcare initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

MMS

Maximus

$63.51

0.24 (0.38%)

06:35
08/14/18
08/14
06:35
08/14/18
06:35
Hot Stocks
Maximus receives North Carolina DHHS contract to provide Medicaid services »

Maximus announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYH

Community Health

$3.15

0.06 (1.94%)

06:34
08/14/18
08/14
06:34
08/14/18
06:34
Initiation
Community Health initiated  »

Community Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 22

    Aug

CHAP

Chaparral Energy

$17.77

(0.00%)

06:33
08/14/18
08/14
06:33
08/14/18
06:33
Earnings
Chaparral Energy reports Q2 EPS (49c) with items, consensus 9c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

AAP

Advance Auto Parts

$144.79

-1.52 (-1.04%)

06:33
08/14/18
08/14
06:33
08/14/18
06:33
Earnings
Advance Auto Parts sees FY18 revenue $9.3B-$9.5B, consensus $9.38B »

Sees FY18 SSS growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.